You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Article info

Article menu

Download PDFPDF

XML
Clinical trials monitor
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

Authors

  • Dmitriy Zamarin Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Medicine, Weill-Cornell Medical College, New York, NY, United States Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, United States Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Sven Walderich Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Aliya Holland Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Qin Zhou Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Alexia E Iasonos Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Jean M Torrisi Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Taha Merghoub Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, United States Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, United States Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA PubMed articlesGoogle scholar articles
  • Lewis F Chesebrough Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Autumn S Mcdonnell Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Jacqueline M Gallagher Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Yanyun Li Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Travis J Hollmann Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States PubMed articlesGoogle scholar articles
  • Rachel N Grisham Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Medicine, Weill-Cornell Medical College, New York, NY, United States PubMed articlesGoogle scholar articles
  • Courtney L Erskine Department of Immunology, Mayo Clinic, Rochester, MN, United States PubMed articlesGoogle scholar articles
  • Mathew S Block Department of Oncology, Mayo Clinic, Rochester, MN, United States PubMed articlesGoogle scholar articles
  • Keith L Knutson Department of Immunology, Mayo Clinic, Rochester, MN, United States PubMed articlesGoogle scholar articles
  • Roisin E O’Cearbhaill Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Medicine, Weill-Cornell Medical College, New York, NY, United States PubMed articlesGoogle scholar articles
  • Carol Aghajanian Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Medicine, Weill-Cornell Medical College, New York, NY, United States PubMed articlesGoogle scholar articles
  • Jason A Konner Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Medicine, Weill-Cornell Medical College, New York, NY, United States PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Dmitriy Zamarin; zamarind{at}mskcc.org
View Full Text

Citation

Zamarin D, Walderich S, Holland A, et al
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
Journal for ImmunoTherapy of Cancer 2020;8:e000829. doi: 10.1136/jitc-2020-000829

Publication history

  • Accepted April 14, 2020
  • First published June 4, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.